With Black women and straight men increasingly at risk, Gilead’s Yeztugo may finally offer a discreet, stigma-free way to ...

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

"Gilead wins positive European approval opinion for twice-yearly HIV injection" was originally created and published by ...

Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...

Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, ...

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...

The U.S. alone sees 700 new cases and 100 HIV-related deaths each week, Gilead CEO Daniel O'Day said in an interview ahead of the approval.

After purging the CDC’s vaccine advisory committee and replacing it with his own appointments, U.S. Health Secretary Robert F ...

Pharma giant Gilead Sciences agreed to pay hundreds of millions of dollars to state health insurance programs after admitting to a years-long kickback scheme to promote its panel of HIV medications.

Attorney General Dave Sunday announced that Pennsylvania will receive over $1 million as part of a $202 million multistate settlement with Gilead Sciences, Inc. over an illegal kickback scheme to ...

In one late-stage trial, 99.9% of patients who took Gilead's injection did not contract an infection. There were only two cases among more than 2,000 patients, effectively reducing the risk of HIV ...

The Food and Drug Administration on Wednesday approved Gilead's twice-yearly antiviral injection for preventing HIV — a milestone that the company and some experts say could help bring the world ...